lilly
Lilly, Biogen and Roche debut Alzheimer’s disease drug results
July 22, 2015Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly
Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …
Lilly and Immunocore collaborate on melanoma
June 29, 2015Research and Development, Sales and Marketing LY2157299, LY2801653, brett wells, immunocore, lilly
Eli Lilly is teaming up again with UK biotech Immunocore in order to work together on immunotherapy-based clinical trials. Specifically …
UK Court weighs in on Lilly-Actavis Alimta case
June 26, 2015Medical Communications, Sales and Marketing Actavis, Alimta, UK, lilly
Actavis will be infringing Lilly’s patent if it were to produce generic versions of Alimta, the UK Court of Appeal …
Lilly and Novartis face legal challenges
June 25, 2015Medical Communications, Sales and Marketing Gleevec, Glivec, Novartis, cymbalta, imatinib, lilly, zyprexa
Judges in California have ruled that Lilly should face claims it failed to fully disclose the extent of post-withdrawal side …
DrugDev looks to Lilly for chairman role
June 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drugdev, jeffrey kasher, lilly
Dr Jeffrey Kasher has joined US healthcare tech firm DrugDev as the chairman of its advisory board. Kasher takes 28 …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
Two new diabetes drugs approved
May 28, 2015Sales and Marketing Japan, Takeda, diabetes in China, lilly
Two new diabetes offerings from Lilly and Takeda are now available for patients in the US and Japan after they …
Bayer wins Cancer Drugs Fund appeal
May 22, 2015Sales and Marketing Bayer, CDF, Cancer Drugs Fund, Eisai, NHS, lilly
Bayer is the only company to win its appeal to NHS England in the latest round of Cancer Drugs Fund …
FDA issues more diabetes drug warnings
May 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Boehringer, J&J, JJ, lilly
The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …
Takeda pays $2.7 billion to settle Actos lawsuits
May 1, 2015Sales and Marketing Actos, FDA, Takeda, bladder, lilly, pioglitazone, type 2
Takeda has agreed to pay $2.7 billion to finally settle thousands of US lawsuits claiming its diabetes drug Actos can …
Sanofi rules out Toujeo discount in diabetes
April 14, 2015Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo
Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …
Pfizer is pharma’s biggest advertiser
March 31, 2015Medical Communications, Sales and Marketing AbbVie, AstraZeneca, Pfizer, advertising, adverts, dtc, lilly
US giant Pfizer spends far more on direct-to-consumer advertising than any other pharma firm according to new data from Kantar …
EMA committee recommends five drugs for approval
March 30, 2015Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly
Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …
Lilly and Boehringer diabetes drug sees US launch
March 24, 2015Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …
FDA lifts ban on Pfizer Lilly pain study
March 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Pfizer, lilly, pain, tanezumab
Pfizer and Eli Lilly will resume Phase III clinical trials of tanezumab following the FDA lifting a ban on trials …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
